INX-315, a CDK2 inhibitor, gained FDA fast track status in CCNE1-positive platinum-resistant/refractory ovarian cancer.

Here is a recap of every FDA approval announced by the regulatory agency in the month of April, spanning various cancer types ...

The immune system is comprised of two separate active arms of immunity to provide robust protection against disease. The two separate systems of immunity i | Immunology ...

INX-315, a CDK2 inhibitor, received FDA fast track designation for patients with CCNE1-amplified platinum-resistant ovarian ...

In solid tumors, such as skin ... PRAME is produced by many tumors, such as melanoma, ovarian cancer, sarcomas, and lung ...

Ovarian cysts are fluid-filled sacs that form on or inside the ovaries for a variety of reasons. Often, they disappear on ...

The selective CDK2 inhibitor INX-315 has been given FDA fast track designation for use in CCNE1-amplified, platinum-resistant ...

The AERIAL trial will assess LEU011, which has MHRA Innovation Passport status, for solid tumors, a challenging area compared ...

L2 antibody with cytotoxic killing function is designed to treat the many “immune-excluded” cancers that are resistant to ...

Fast Track designation highlights potential of INX-315 to address unmet need for patients with recurrent advanced/metastatic ...

In recent years, cell therapies have developed alongside chemotherapy and immunotherapy to become a new pillar in the treatment of patients with blood and lymph gland cancer. In solid tumors, such as ...